Access to Information Requests Completed - February 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may

contact the Access to Information and Privacy Division.

For the month of February 2013

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-00114	All documents pertaining to any trade or consumer complaint filed against the following company: Nutravital Inc; specifically with respect to their sale, marketing, or advertising of foods or drug products, including natural health products.	Disclosed in part	193
A-2010-00532	All documents related to an infant formula company with the following brand name: Heinz. (Jan 1, 2007 to Jul 28, 1010).	Disclosed in part	277
A-2010-01165	All correspondence from Physicians for Smoke-Free Canada. (Oct 15, 2008 to Jan 20, 2011).	Disclosed in part	2,937
A-2010-01263	All emails written to or from Samuel Godefroy about the future of the Sodium Working Group. (Jul 1, 2010 to Feb 7, 2011).	Disclosed in part	185
A-2011-00564	List of studies that were reviewed, considered and/or relied upon with respect to these studies: Initial registration of the technical grade active ingredient of Pursuit Technical Herbicide AC 263,499 (PCP21536), Pursuit Herbicide (PCP21537), and Pursuit 240 (PCP23844).	Disclosed in part	323
A-2011-00568	Documents related to the substance Borax (B4Na207.10H20) (Chemical Abstract Services Registry Number 1303-96-4) regarding its uses and risks associated with its use. (Jan 1, 1984 to Aug 3, 2011).	Disclosed in part	1,395
A-2011-01025	Information regarding the product Lucentis (ranibizumab injection) by Novartis Pharmaceuticals.	Disclosed in part	559
A-2011-01032	All documents regarding Tribenuron Methyl Technical Herbicide (Registration Number 22330). (Mar 1, 2009 to Sep 9, 2011).	Disclosed in part	194
A-2011-01039	All documents regarding Thifensulfuron Methyl. (Mar 1, 2009 to Sep 9, 2011).	Disclosed in part	92
A-2011-01041	All documents regarding Tribenuron Methyl Technical Herbicide (Registration Number 21060). (Mar 1, 2009 to Sep 9, 2011).	Disclosed in part	70
A-2011-01440	Information regarding the product Silicon Gel; Biosilica Plus, NPN 80023510 by Vitaminol Inc.	Disclosed in part	33
A-2011-01582	Information regarding the product Peridex Oral Rinse, DIN 02237452 by 3M Canada Company.	Disclosed in part	65
A-2011-01668	All internal reports/communications/minutes from 2011 and 2012 regarding potential changes to medical cannabis access, production, and distribution.	Disclosed in part	191
A-2012-00029	External correspondence to and from the Minister of Health concerning the Food Mail Program and/or Nutrition North Canada. (Nov 1, 2008 to Mar 31, 2012).	Disclosed in part	344
A-2012-00066	AERs for the product Cymbalta. Report numbers: 000380546, 000381430, 000381433, 000381613, 000381872, 000384893, 000387309 , 000389748, 000395056, 000395286, 000397830, 000383893, 000386303 and 000386480.	Disclosed in part	27
A-2012-00189	Documents from the Assistant Deputy Minister (and above) regarding the government's decision to close Assisted Human Reproduction Canada effective March 1 2013. (Nov 1, 2011 to Dec 1, 2011).	Disclosed in part	9
A-2012-00516	All documents about so-called pink slime in ground beef (burgers). (Jul 1, 2011 to Dec 31, 2011).	All disclosed	12
A-2012-00517	All documents about so-called pink slime in ground beef (burgers). (Jan 1, 2012 to Jun 30, 2012).	Disclosed in part	39
A-2012-00587	Documents on services that are provided by Health Canada to aboriginal adults with disabilities living on reserve and in northern aboriginal communities, on how those services are delivered, on the level of care expected, and on the specific types and amounts of funding for those services per regions and nationally. (Jan 1, 2010 to Jul 23, 2012).	Disclosed in part	656
A-2012-00694	AERs for the product BIAXIN. Report number: 000375713.	Disclosed in part	3
A-2012-00697	All documents relating to personal harm and injury caused by the drug CIPRALEX (Escitalopram), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012). (Jan 1, 2005 to Aug 8, 2012).	Disclosed in part	54
A-2012-00698	All documents relating to personal harm and injury caused by the drug PROZAC (fluoxetine hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012).	Disclosed in part	56
A-2012-00719	All documents relating to personal harm and injury caused by the drug PROZAC (fluoxetine hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012). (Jan 1, 2005 to Aug 8, 2012).	Disclosed in part	45
A-2012-00769	Information regarding the product Vimovo, DINs 02361701 and 02361728 by Astrazeneca Canada Inc.	Disclosed in part	249
A-2012-00806	Information regarding the product DRX GERMICIDAL DETERGENT by Wyant.	Disclosed in part	133
A-2012-00836	All follow-up documents regarding the meeting between the Canadian Cosmetic, Toiletry and Fragrance Association and Paul Glover, held May 31 2012.	Disclosed in part	6
A-2012-00839	All documents mentioning the Canadian Lung Association. (Sep 1, 2011 to Aug 22, 2012).	Disclosed in part	115
A-2012-00871	Information regarding the medical device HDCKIT SYSTEM - HDCKIT, License number 88251 by NEWRONIKA SRL.	Disclosed in part	123
A-2012-00892	All documents pertaining to project or funding agreements with subsequent deliverables for: Non-Smokers' Rights Association (NSRA), Physicians for a Smoke Free Canada (PSC) and Canadian Council on Tobacco Control (CCTC). (Oct 1, 2011 to Aug 31, 2012).	Disclosed in part	3,952
A-2012-00898	Copy of the final feasibility report with respect to the Request For Proposal #1000128834, project title: A feasibility Study for Developing an International Collaboration Program with Foreign Jurisdictions to Assess Generic Drug Submissions.	All disclosed	63
A-2012-00901	All approved Product Monographs for the product Heparin by Sandoz.	All disclosed	14
A-2012-00951	Information regarding the product Colgate Optic White, NPN 80025365.	Disclosed in part	198
A-2012-00952	Information regarding the product Colgate Optic White, NPN 80025536.	Disclosed in part	192
A-2012-00959	Information regarding the product Cold-Defense; Health first - Cold - Defense, NPN 80030770 by Accurex Health Care Manufacturing Inc.	Disclosed in part	94
A-2012-00993	All documentation related to the planning and implementation of British Columbia Tripartite First Nations Health (BC Tripartite) regarding amounts paid. (Apr 1, 2007 to Mar 31 2012).	All disclosed	64
A-2012-00996	All documentation related to the planning and implementation of British Columbia Tripartite First Nations Health (BC Tripartite) regarding transfer payment agreements. (Apr 1, 2007 to Mar 31 2012).	All disclosed	590
A-2012-01004	Information regarding the product Claritin (loratadine), by Schering-Plough Canada Inc.	Disclosed in part	85
A-2012-01005	All documents that enabled Health Canada officials to obtain the conclusion regarding complaint 64180 (submitted May 3, 2011), according to the provisions outlined in the Health Canada document: Guidance to Industry - How to Submit a Trade Complaint GUI-0038.	All disclosed	16
A-2012-01021	All documents that enabled Health Canada officials to obtain the conclusion regarding complaint 64178 (submitted May 3, 2011), according to the provisions outlined in the Health Canada document: Guidance to Industry - How to Submit a Trade Complaint GUI-0038.	Disclosed in part	69
A-2012-01023	All documents that enabled Health Canada officials to obtain the conclusion regarding complaint 62509 (submitted November 23, 2010), according to the provisions outlined in the Health Canada document: Guidance to Industry - How to Submit a Trade Complaint GUI-0038.	All disclosed	38
A-2012-01028	All documents of the article entitled "Using a change in percentage highly annoyed with noise as a potential health effect measure for projects under the Canadian Environmental Assessment Act" Canadian Acoustics, 36(2): 13-28 (2008) by Michaud, Bly, and Keith.	Disclosed in part	989
A-2012-01046	Information regarding the product Colgate Sensitive Pro-Relief Mouthwash, NPN 80035684.	Disclosed in part	78
A-2012-01053	The standard operating procedure referenced in the Draft Guidance Document: The use of foreign reviews by Health Canada and revisions to the use of foreign reviews pilot project September 28, 2012.	All disclosed	75
A-2012-01054	Information regarding the product Colgate Sensitive Pro-Relief Mouthwash, NPN 80035527.	Disclosed in part	98
A-2012-01076	Information regarding the product Oil of Oregano & Vitamin E, NPN 80036035 by W/N Pharmaceuticals Ltd.	Disclosed in part	53
A-2012-01086	All documents about the issuing of October 10, 2012 safety advisory not to mix alcohol and energy drinks.	All disclosed	40
A-2012-01088	Documents regarding XL Foods, the recall and the E. coli outbreak. (Sep 1, 2012 to Oct 29, 2012).	Disclosed in part	54
A-2012-01089	Briefing notes prepared for the minister. (Oct 1, 2012 to Oct 30, 2012).	Disclosed in part	142
A-2012-01122	Information regarding the medical device ZUIDEX, License number 63470 by Q-Med AB.	Disclosed in part	12
A-2012-01167	Documents regarding the contract awarded from the Request For Proposal #1000140992 Indigenous Community Development Facilitation as part of the Community Development and Capacity Building Division of First Nations and Inuit Health Branch.	Disclosed in part	61
A-2012-01208	Information regarding the product Factive, DIN 02248968 by Oscient Pharmaceuticals Corporation with respect to the maximum non-excessive price.	No records exist	0
A-2012-01215	AERs for the product ULORIC (febuxostat). Report numbers: 000430523 and 000446109.	Disclosed in part	6
A-2012-01216	AERs for the product Pantoloc. Report numbers: 000431402, 000439573, 000439876, 000441017 and 000446231.	Disclosed in part	11
A-2012-01220	AER for the product Daxas (roflumilast). Report number: 000431343.	Disclosed in part	1
A-2012-01223	Information regarding the product Progressive Nutritional Therapies Phytoberry, NPN 80035647 by Body Plus Nutritional Products Inc.	Disclosed in part	26
A-2012-01227	Information regarding the product Progressive Men'S Chewable Multiple Vitamins And Minerals Tablets, NPN 80036793 by Body Plus Nutritional Products Inc.	Disclosed in part	12
A-2012-01228	All documents submitted in relation to the InterNoise 2012 trip by David Michaud, Stephen Keith, and Tara Bower.	Disclosed in part	66
A-2012-01229	All documents related to wind energy/wind turbine noise/health impacts of wind turbines: Between Health Canada and any representative and/or employee Australia's National Health and Medical Research Council. (Jan 1, 2010 to Nov 26, 2012).	Disclosed in part	22
A-2012-01232	All documents that relate to: "Canada calls for a federal framework or mechanism to ensure that the health impacts of new technologies or other mitigation measures are adequately assessed before they are widely deployed or commercialized" described in Health Policy Research Issue 11, November 2005.	Disclosed in part	290
A-2012-01234	All documents concerning a letter dated August 6, 2009, Subject: Health Canada's response to the Digby Wind Power Project Addendum, Digby, Nova Scotia, Signed by Allison Denning, Regional Environmental Assessment Coordinator.	Disclosed in part	481
A-2012-01236	All documents relating to INTERNOISE 2012 (New York Conference). (Jul 20, 2012 to Dec 3, 2012).	Disclosed in part	198
A-2012-01242	Statistical data regarding the number of persons who hold an Authorization to Possess dried marihuana under the Medical Marihuana Medical Access Regulations. (2011 and 2012).	All disclosed	1
A-2012-01243	Statistical data regarding the number of persons who are currently allowed (possess a license) to cultivate or produce marihuana for medical purposes divided by Personal Use production Licence and Designated-Person Licence under the Medical Marihuana Medical Access Regulations. (2011 and 2012).	All disclosed	1
A-2012-01269	All AERs related to Sanofi Pasteur health products.	Disclosed in part	18
A-2012-01280	List of all prescription medications withdrawn from the Canadian market. (Jan 1, 2006 to Dec 5, 2012).	Disclosed in part	5
A-2012-01286	AERs for the product Celexa (citalopram). Report numbers: 000160558, 000157962, 000174806, 000168773, 000164187, 000169572, 000169099, 000173018, 000145788 and 000173940.	Disclosed in part	23
A-2012-01290	Information regarding the medical device Gynecare Prolift Device by Johnson & Johnson Inc.	Disclosed in part	31
A-2012-01297	Information regarding the product Choline Alfoscerate, NPN 80036901 by 1669652 Alberta Ltd.	All exempted	0
A-2012-01303	AER for the product Betaseron. Report number: 000446400.	Disclosed in part	2
A-2012-01310	AERs for the product Yasmin. Report numbers: 000441766, 000442747, 00442802, 000442815 and 000445321.	Disclosed in part	6
A-2012-01311	AER for the product Zevalin. Report number: 000443355#.	Disclosed in part	3
A-2012-01313	All business expense claims filed for reimbursement by Sandra Buckler, Chief of Staff to the Minister, from the times of Ms. Buckler joining Health Canada to December 3, 2012.	Disclosed in part	28
A-2012-01344	All documents, both internal and publicly accessible, regarding established and/or reported side effects and/or adverse effects and/or drug interactions relating to the drug Propofol. (Jan 1, 2009 to Jan 21, 2013).	No records exist	0
A-2012-01359	AER. Report number: 000330727.	Disclosed in part	3
A-2012-01362	Substantive documents making reference to Health Canada and/or Aboriginal Affairs and Northern Development Canada services to Aboriginal adults with disabilities living in remote and isolated communities. (Jan 1, 2010 to Dec 19, 2012).	All disclosed	86
A-2012-01373	All documents, both internal and publicly accessible, regarding established and/or reported side effects and/or adverse effects and/or drug interactions relating to the drug Propofol.	All disclosed	47
A-2012-01374	All documents, both internal and publicly accessible, regarding established and/or reported side effects and/or adverse effects and/or drug interactions relating to the drug Ancef (Cefazolin). (Jan 1, 2009 to Jan 21, 2013).	No records exist	0
A-2012-01379	All documents, both internal and publicly accessible, regarding established and/or reported side effects and/or adverse effects and/or drug interactions relating to the drug Demerol. (Jan 1, 2009 to Jan 21, 2013).	No records exist	0
A-2012-01391	Information regarding the product Ralivia (tramadol hydrochloride), DIN 02299791, 02299208 and 02299216 by Valeant Canada LP/Valeant Canada S.E.C.	No records exist	0
A-2012-01397	Information regarding the product Eurax Cream 10%, DIN 00623377 by Columbia Laboratories Canada Inc.	No records exist	0
A-2012-01398	Information regarding the product Kwellada-P Lotion, DIN 02231348 by Medtech Products Inc.	No records exist	0
A-2012-01399	Information regarding the product Kwellada-P Crème Rinse, DIN 02231480 by Medtech Products Inc.	No records exist	0
A-2012-01401	Information regarding the product NIX CREME RINSE, DIN 00771368 by Insight Pharmaceuticals LLC.	No records exist	0
A-2012-01402	Information regarding the product NIX DERMAL CREAM, DIN 02219905 by Glaxosmithkline Consumer Healthcare Inc.	No records exist	0
A-2012-01404	Information regarding the product R & C Shampoo, DIN 02125447 by Medtech Products Inc.	No records exist	0
A-2012-01413	All information and communications between the Ontario Ministry of Environment and Health Canada regarding adverse health issues associated with industrial wind turbine operations and electrical pollution.	No records exist	0
A-2012-01423	All call-ups and contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of December 2012.	Disclosed in part	27
A-2012-01424	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during December 2012.	All disclosed	2
A-2012-01429	The names and contact information (HOLDER OF AUTHORIZATION INFORMATION) of all of the persons who have obtained 'Authorization To Possess Dried Marihuana for Medical Purposes' (as per section 11 of Marihuana Medical Access Regulations) in British Columbia, Alberta, Saskatchewan, and Manitoba. (Jul 02, 2011 to Dec 31, 2012).	All exempted	0
A-2012-01430	The names and contact information (HOLDER OF AUTHORIZATION INFORMATION) of all of the persons who have obtained 'Personal - Use Production Licence Dried Marihuana for Medical Purposes' (as per section 29 of Marihuana Medical Access Regulations) in British Columbia, Alberta, Saskatchewan, and Manitoba. (Jul 02, 2011 to Dec 31, 2012).	All exempted	0
A-2012-01432	List of every drug where a Special Access Program request was granted for the year 2012.	All disclosed	6
A-2012-01443	A listing of the Access to Information requests submitted to Health Canada. (Dec 1, 2012 to Dec 31, 2012).	Disclosed in part	9
A-2012-01454	AERs for the product Xanax (Alprazolam). (Jan 1, 2011 to Dec 31, 2012).	Disclosed in part	12
A-2012-01455	AERs for the product Valium (Diazepam). (Jan 1, 2011 to Dec 31, 2012).	Disclosed in part	16
A-2012-01456	AERs for the product Klonopin (Clonazepam). (Jan 1, 2011 to Dec 31, 2012).	No records exist	0
A-2012-01458	AERs for the product Mavik. Report numbers: 000403709, 000406603 and 000411793.	Disclosed in part	3
A-2012-01461	AER for the product Avelox. Report number: 000451734.	Disclosed in part	1
A-2012-01462	AERs for the product Gadovist. Report numbers: 000449066, 000451742 and 000451636.	Disclosed in part	3
A-2012-01463	AERs for the product Magnevist. Report numbers: 000451850 and 000450849.	Disclosed in part	2
A-2012-01464	AER for the product Staxyn. Report number: 000451905.	Disclosed in part	1
A-2012-01465	AERs for the product Xarelto. Report numbers: 000453222 and 000449005.	Disclosed in part	2
A-2012-01466	AERs for the product Yasmin. Report numbers: 000451184 and 000450110.	Disclosed in part	5
A-2012-01467	AERs for the product Yaz. Report numbers: 000447048, 000451200 and 000447694.	Disclosed in part	4
A-2012-01472	AERs. Report numbers: 000389827 and 000389622..	Disclosed in part	4
A-2012-01475	Information regarding the Natural Health Product Redline RTD.	Disclosed in part	160
A-2012-01478	AER. Report number: 000459492.	Disclosed in part	7
A-2012-01479	AER. Report numbers: 000452324.	Disclosed in part	2
A-2012-01480	AER. Report number: 000460533.	Disclosed in part	1
A-2012-01483	AER for the product Fluanxol. Report number: 000459967.	Disclosed in part	1
A-2012-01490	AER. Report number: 000461896.	Disclosed in part	1
A-2012-01491	AER. Report number: 000461908.	Disclosed in part	1
A-2012-01492	AER. Report number: 000457607.	Disclosed in part	1
A-2012-01493	AER. Report number: 000464753.	Disclosed in part	1
A-2012-01494	AER. Report number: 000465296.	Disclosed in part	2
A-2012-01498	A copy of any subsequent contract/contribution agreement between Health Canada and Sioux Lookout First nation Health Authority for the ongoing maintenance and running of the Hostel.	No records exist	0
A-2012-01503	Information concerning the volume of sales of ACTOS in Canada.	No records exist	0
A-2012-01505	Any information concerning whether doctors were properly monitoring patients on ACTOS.	No records exist	0
A-2012-01517	Most recent guidelines and/or regulations used by Health Canada's Natural Health Products Directorate to assess license applications for liquid caffeinated products (energy shots).	No records exist	0
A-2012-01521	All information regarding the recruitment plus hiring process for position vacancy at Eagle Ridge Hospital (Fraser Health Authority) posting # 91044 Position Control # 032603 Health Sciences Association posting date December 20, 2012: Recreation Therapist Classification Paramedical Grid Level 8 Rehabilitation Program.	No records exist	0
A-2012-01523	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during January 2013.	All disclosed	4
A-2012-01536	All documents related to the reclassification of methylendioxymethamphetamine (MDMA) for use in a therapeutic setting for treatment of people suffering from post-traumatic stress disorder (PTSD) for 2012.	No records exist	0
A-2012-01538	All documents related to the reclassification of methylendioxymethamphetamine (MDMA) for use in a therapeutic setting for treatment of people suffering from post-traumatic stress disorder (PTSD) for 2011.	No records exist	0
A-2012-01539	All documents related to the reclassification of methylendioxymethamphetamine (MDMA) for use in a therapeutic setting for treatment of people suffering from post-traumatic stress disorder (PTSD) for 2010.	No records exist	0
A-2012-01540	All documents related to the reclassification of methylendioxymethamphetamine (MDMA) for use in a therapeutic setting for treatment of people suffering from post-traumatic stress disorder (PTSD) for 2009.	No records exist	0
A-2012-01573	AERs. Report numbers: 000395843, 000405718, 000412509, 000419173, 000423170, 000427455, 000432278 and 0004444085.	Disclosed in part	11